Journey Medical Corporation
NASDAQ:DERMDrug Manufacturers - Specialty & Generic
+$0.06 today
- Market cap
- $104.15M
- Beta
- 1.10
- P/E (TTM)
- -17.0
- EPS (TTM)
- -$0.35
Volume 0.25M
Average 0.28M
DERM Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Journey Medical CorporationNASDAQ: DERM
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 29.2% from a year ago
Cash & equivalents stood at $27.22M at the end of Q1 FY2026, up 29.2% from a year earlier and up 13.0% from the prior quarter. Over 3 fiscal years it compounded at -9.0% a year.
Context
- Cash & equivalents amounted to 29.7% of total assets at the end of Q1 FY2026, up 4.9 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +29.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 24.09M USD
- Year-over-year change
- +18.6%
- 4-year CAGR
- -16.3%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 24.09M | +18.6% |
| FY2024 | 2024-12-31 | 20.31M | -26.0% |
| FY2023 | 2023-12-31 | 27.44M | -14.3% |
| FY2022 | 2022-12-31 | 32M | -34.8% |
| FY2021 | 2021-12-31 | 49.08M | — |
Cash & Equivalents vs competitors
How DERM compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +29.2% is the 5th highest of 10, against a peer median of +16.7%.
- Cash & equivalents amounts to 29.7% of total assets for DERM, versus a peer median of 39.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $176.96M USD | -28.5% | +33.4% | 46.7% | |
| Mar 2026 | $118.64M USD | -34.2% | +5.5% | 41.1% | |
| Dec 2025 | €99.27M EUR | +2.8% | +4.6% | 39.9% | |
| Mar 2026 | CA$54.08M CAD | +310.3% | — | 10.3% | |
| Mar 2026 | $44.65M USD | +16.7% | -47.9% | 55.8% | |
| Mar 2026 | $40.18M USD | +77.2% | +15.6% | 55.9% | |
| Mar 2026 | $28.37M USD | +54.6% | +20.6% | 28.2% | |
| Mar 2026 | $27.22M USD | +29.2% | -9.0% | 29.7% | |
| Mar 2026 | €12.98M EUR | -42.0% | +18.8% | 13.3% | |
| Mar 2026 | $4.4M USD | +296.3% | -20.6% | 2.2% | |
| Peer median (excluding DERM) | — | +16.7% | +10.6% | 39.9% | |
Competitors are the stored peer set for DERM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 49.08M | 32M | 27.44M | 20.31M | 24.09M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 23.11M | 28.21M | 15.22M | 10.23M | 29.78M |
| Inventory | 9.86M | 14.16M | 10.21M | 14.43M | 9.62M |
| Other Current Assets | 2.44M | 3.31M | 3.59M | 3.21M | 3.38M |
| Total Current Assets | 84.49M | 77.68M | 56.46M | 48.18M | 66.87M |
| Property, Plant & Equipment (Net) | 89K | 189K | 101K | 199K | 111K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 12.55M | 27.2M | 20.29M | 31.86M | 27.61M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 150K | 95K | 6K | 0 | 0 |
| Total Non-current Assets | 12.79M | 27.48M | 20.39M | 32.06M | 27.72M |
| Total Assets | 97.28M | 105.16M | 76.85M | 80.24M | 94.59M |
| Account Payables | 22.81M | 36.98M | 16.08M | 16.05M | 9.31M |
| Short-term Debt | 812K | 2.95M | 3M | 625K | 0 |
| Tax Payables | 8K | 35K | 53K | 60K | 70K |
| Deferred Revenue | 0 | 0 | 53K | 0 | 0 |
| Other Current Liabilities | 24.59M | 14.1M | 4.08M | 14.45M | 9.57M |
| Total Current Liabilities | 51.61M | 66.83M | 41.87M | 35.18M | 37.44M |
| Long-term Debt | 3.63M | 19.83M | 14.62M | 24.88M | 25.28M |
| Deferred Tax Liabilities | 8K | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | (8K) | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 3.64M | 1.41M | 0 | 0 | 0 |
| Total Non-current Liabilities | 3.64M | 21.35M | 14.63M | 25M | 25.3M |
| Total Liabilities | 55.24M | 88.18M | 56.5M | 60.17M | 62.74M |
| Common Stock | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | (38.87M) | (68.5M) | (72.36M) | (87.03M) | (98.46M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 42.04M | 16.98M | 20.35M | 20.07M | 31.85M |
| Total Debt | 910K | 22.97M | 17.73M | 25.71M | 25.4M |
| Net Debt | (48.17M) | (9.04M) | (9.71M) | 5.4M | 1.31M |
Journey Medical Corporation
NASDAQ:DERM
Intrinsic Alpha fair value
Locked
Current Price
$3.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.